Clinical Report: The Role of RFX5 in Cancer: Contextual Molecular Functions

Overview

RFX5 is identified as a context-dependent transcriptional integrator. Its role varies across tumor types, particularly in hepatocellular carcinoma (HCC) and immune-inflamed tumors.

Background

Understanding the molecular functions of RFX5 is crucial as it presents a dual role in cancer, acting both as a promoter of tumor growth in certain contexts and enhancing immune surveillance in others.

Data Highlights

No specific numerical data or trial results were provided in the source material.

Key Findings

• RFX5 is amplified in hepatocellular carcinoma (HCC), promoting proliferation and apoptosis resistance via the YWHAQ–PI3K/Akt axis.
• In immune-inflamed tumors, RFX5 enhances antigen presentation and CD8+ T-cell infiltration.
• RFX5 expression correlates with clinical prognosis and immune checkpoint blockade response in specific tumor types.
• Current evidence does not support RFX5 as an independent predictive biomarker.
• RFX5's functions are dynamically influenced by tumor lineage and microenvironmental immune cues.

Clinical Implications

Current evidence does not support RFX5 as an independent predictive biomarker.

Conclusion

RFX5 presents a complex interplay of functions in cancer.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Frontiers in Medicine — Out“FOX”ing cancer: the implications of FOXC2 as a putative predictive biomarker for cancer immunotherapy
4. Frontiers in Oncology — FOXA2 in cancer: from fundamental biology to clinical translation
5. Frontiers in Oncology — C5orf46: a promising prognosis risk indicator with implication in the remodeling of KIRC and pan-cancer tumor microenvironments
6. Frontiers in Oncology — The Role of Homeobox Genes in Signaling Pathway Positive Feedback Loops and Cancer Therapy
7. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update | Journal of Clinical Oncology
8. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols - PMC
9. RFX5 as a regulator of spatial chromatin contacts and gene expression - PubMed